Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by Brokerages

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $23.1429.

Several equities analysts have recently commented on IMNM shares. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Wedbush restated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a research report on Thursday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday.

Immunome Stock Down 5.6%

Shares of IMNM stock opened at $9.87 on Friday. The company has a market cap of $858.79 million, a P/E ratio of -3.20 and a beta of 1.93. The business has a 50 day moving average of $9.53 and a two-hundred day moving average of $8.92. Immunome has a 52 week low of $5.15 and a 52 week high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative return on equity of 78.93% and a negative net margin of 1,687.08%. The firm had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Jean Jacques Bienaime bought 5,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the acquisition, the director directly owned 36,415 shares in the company, valued at approximately $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in Immunome in the 4th quarter valued at about $70,000. KLP Kapitalforvaltning AS acquired a new position in shares of Immunome in the 4th quarter worth approximately $75,000. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in Immunome during the fourth quarter valued at approximately $95,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Immunome during the first quarter worth approximately $95,000. Institutional investors own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.